GHK-Cu — 50 mg
Copper-binding tripeptide complex studied in fibroblast and preclinical models involving collagen synthesis and extracellular-matrix accumulation.
GLPZone / The research collection
Illustrative certificateNS-2026-06049Nordicstar Analytical Sciences
KLOW 80 MG
99.565%HPLC purity
- Lot
- GLZ-26-KLOW-1048
- Measured content
- 80.64 mg
- Mass-spec identity
- Confirmed
- Endotoxin
- <1.0 EU/mg
- Tested
- 25 Sep 2026
Repair & Recovery
KLOW
GHK-Cu, BPC-157, TB-500 & KPV research formulation
A pair saves 10%. A set of three saves 15%.
For laboratory research use only.
Not for human consumption or clinical use.
Compound details
- Compound
- KLOW
- Form
- Lyophilized
Quality & documentation
The records shown here are illustrative. Request laboratory-issued documentation for your lot before ordering.
- Lot
- GLZ-26-KLOW-1048
- HPLC purity
- 99.565%
- Measured content
- 80.64 mg
- Tested
- 25 Sep 2026
- Report
- NS-2026-06049
Shipping & handling
Priority, tracked shipping within the United States, free on orders of $200 or more after savings. Add Priority dispatch at checkout to have your order packed first; Private Clients receive it on every order. Follow the product documentation for laboratory handling requirements.
Shipping information01 / The compound
Understand
the starting point.
GHK-Cu, BPC-157, TB-500 & KPV research formulation
KLOW is a multi-component research formulation rather than a single peptide or chemical entity. It combines four distinct research compounds, each with its own molecular identity and scientific literature.
Because KLOW is a blend, the complete formulation should not be assigned one CAS number, molecular formula, molecular weight or amino-acid sequence. Those identifiers apply to the individual components instead.
02 / Research profile
The pathways.
The possibilities.
In current research-supply terminology, GLOW commonly refers to a three-component GHK-Cu, BPC-157 and TB-500 blend, while KLOW adds KPV as a fourth component. These names describe multi-component research formulations rather than individual chemical entities, and exact formulations should always be confirmed from the product label and lot documentation.
BPC-157 — 10 mg
15-amino-acid research peptide investigated primarily in preclinical musculoskeletal and tissue-repair models.
TB-500 — 10 mg
TB-500 is identified in published analytical research as the N-terminally acetylated thymosin beta-4 residues 17–23 fragment Ac-LKKTETQ. It is distinct from full-length thymosin beta-4.
KPV — 10 mg
Lys-Pro-Val tripeptide derived from the C-terminal sequence of α-MSH and studied in inflammatory-signaling and epithelial research models.
Reading the evidence
Published research characterizes the individual components of KLOW more extensively than the complete four-component formulation. The cited literature does not include a peer-reviewed study evaluating GHK-Cu, BPC-157, TB-500 and KPV together as KLOW. Findings from studies of the individual compounds should therefore not be interpreted as evidence that the complete blend produces the same effects or that its four components act synergistically. Component-level literature includes GHK-Cu studies of collagen synthesis and extracellular-matrix accumulation, preclinical BPC-157 research involving tendon and fibroblast models, KPV studies involving inflammatory signaling and epithelial transport, and analytical research identifying TB-500 as the acetylated thymosin beta-4 17–23 fragment Ac-LKKTETQ. A 2026 rat study also compared BPC-157, material identified by the investigators as TB-500, and their combination in an Achilles-tendon model. The 2026 publication did not report the amino-acid sequence or analytical characterization of its TB-500 study material. It is related combination research, not evidence that the exact Ac-LKKTETQ component or complete KLOW formulation was tested. The cited literature does not establish clinical outcomes or synergy for the complete KLOW formulation.
03 / Reference data
The details,
in plain sight.
Reference specifications describe a compound. The final lot documentation identifies the material supplied.
| Compound | KLOW |
|---|---|
| Research area | Repair & Recovery |
| Physical form | Lyophilized |
| Vial options | 80 MG |
| Intended use | Laboratory research only |
Variant amounts are nominal catalog quantities. They are not instructions for use.
What is in the sample?
HPLC separates components under a defined method. Read the reported percentage alongside the chromatogram, wavelength, integration method, and scope of the test.
Is it the expected compound?
Mass spectrometry provides molecular-mass evidence. Identity and chromatographic purity answer different questions; one cannot stand in for the other.
Does the report match the vial?
Connect the product name, variant, lot identifier, report date, and issuing laboratory. A report is useful only when its sample can be linked to the material being reviewed.
Independent analysis
Every KLOW lot is analyzed by Nordicstar Analytical Sciences for identity, content, and purity by HPLC with LC-MS confirmation. Each certificate carries a report number and verification key that can be checked at nordicstarlabs.com/verify. Research references below describe published science, not a certificate for a vial.
Read a COA with confidence| Presentation | Lot | HPLC purity | Tested | Certificate |
|---|---|---|---|---|
| 80 MG Current lot | GLZ-26-KLOW-1048 | 99.565% | 25 Sep 2026 | NS-2026-06049 |
| 80 MG | GLZ-26-KLOW-752 | 99.585% | 16 Aug 2026 | NS-2026-06169 |
| 80 MG | GLZ-26-KLOW-652 | 99.562% | 10 Jul 2026 | NS-2026-06170 |
05 / Storage & handling
Care for
the material.
Keep sealed research material protected from moisture, unnecessary light and temperature fluctuations. Use the storage conditions documented for the specific compound, formulation and lot.
Solution stability depends on solvent, concentration, container and experimental conditions. Use a validated laboratory protocol; a universal post-reconstitution shelf life is not established by the literature summaries.
Explore the handling guide06 / Common questions
A little more
understanding.
What is KLOW Peptide Blend?
KLOW is a four-component research formulation containing GHK-Cu, BPC-157, TB-500 and KPV. The nominal 80 mg formulation contains 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV.
Is KLOW one peptide?
No. KLOW contains four distinct compounds in one lyophilized vial. Because it is a mixture rather than a single molecule, KLOW itself does not have one molecular weight, molecular formula, CAS number or amino-acid sequence.
What is the difference between KLOW and GLOW?
In research-supply terminology, GLOW commonly refers to a blend of GHK-Cu, BPC-157 and TB-500. KLOW contains those three components plus KPV. Exact formulations can differ between suppliers, so composition should be confirmed from the specific product label and documentation.
Has the complete KLOW blend been studied?
Published research primarily evaluates the individual KLOW components rather than all four compounds together. The cited literature does not include a peer-reviewed study evaluating GHK-Cu, BPC-157, Ac-LKKTETQ TB-500 and KPV together as the complete KLOW formulation. Component-level findings should not be interpreted as evidence of synergistic or clinical effects for KLOW.
07 / Further reading
Go to
the source.
Selected literature for context. Read each study’s methods, experimental model, and limitations alongside its findings.
- 01Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343–346. DOI: 10.1016/0014-5793(88)80509-X. pubmed.ncbi.nlm.nih.gov / Published literature
- 02Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation. 1993;92(5):2368–2376. DOI: 10.1172/JCI116842. pubmed.ncbi.nlm.nih.gov / Published literature
- 03Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780. DOI: 10.1152/japplphysiol.00945.2010. pubmed.ncbi.nlm.nih.gov / Published literature
- 04
- 05
- 06Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4(9):733–738. DOI: 10.1002/dta.1402. pubmed.ncbi.nlm.nih.gov / Published literature
Curated pairings
